Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • clemcaldwell clemcaldwell Feb 22, 2013 1:55 PM Flag

    Ernie-hbomb

    In the last few days you two had a lengthy discourse;I can't recall the subject exactly.I just wonder if I got the correct impression.It lead me to think you were saying Cabo's affect waned for the patients in the trails.Or that the Cancer found a way to avoid the affects of the Cabo treatment.Am I assuming correctly?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • "It lead me to think you were saying Cabo's affect waned for the patients in the trials." Yes that is one of the main things I was discussing. The experience so far is that eventually all patients taking cabo develop resistance to the treatment and the disease resumes progression. Some patients with less aggressive disease have remained on treatment for 1-2 years, others for only a few months. The real subject of the discussion was to look at some of the statistics and try to tease out a feeling for how long a typical CRPC patient coninues to benefit before their disease resumes progression and think about how much of that interval might translate into increased survival. It's largely conjecture, but it passes the time.

      In the RDT trial 2/3 of the patients had a reported bone scan response. Measurement of the duration of that response started at the 6 week point on trial and the median duration of that response was 5.4 months. If we look at another statistic, progression free survival, the median time to progression free survival for all patients (includes the 1/3 without a bone response) was 6.5 months. So Clem it appears to me that at the 100mg dose, a typical patient received a interval of about 5-6 months in which the radiologically determined extent of their disease did not get worse. We do not know what part of this will translate into a survival benefit, but there is reason to be optimistic.

 
EXEL
5.73+0.19(+3.43%)Jul 31 4:00 PMEDT